JP2014516924A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516924A5 JP2014516924A5 JP2014504013A JP2014504013A JP2014516924A5 JP 2014516924 A5 JP2014516924 A5 JP 2014516924A5 JP 2014504013 A JP2014504013 A JP 2014504013A JP 2014504013 A JP2014504013 A JP 2014504013A JP 2014516924 A5 JP2014516924 A5 JP 2014516924A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- viscosity
- less
- citrate
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473121P | 2011-04-07 | 2011-04-07 | |
| US61/473,121 | 2011-04-07 | ||
| PCT/US2012/032462 WO2012138958A1 (en) | 2011-04-07 | 2012-04-06 | Formulations with reduced viscosity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014516924A JP2014516924A (ja) | 2014-07-17 |
| JP2014516924A5 true JP2014516924A5 (cg-RX-API-DMAC7.html) | 2016-01-28 |
Family
ID=46969561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504013A Pending JP2014516924A (ja) | 2011-04-07 | 2012-04-06 | 粘度が低減された処方物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140023655A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2694100A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014516924A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140018966A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103596585A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2012240050B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013025866A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2832556A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201391488A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL228591A0 (cg-RX-API-DMAC7.html) |
| SG (1) | SG193963A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012138958A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3295957T (pt) * | 2010-01-15 | 2019-11-12 | Kirin Amgen Inc | Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase |
| BR112014010186A2 (pt) * | 2011-10-28 | 2017-05-02 | Integritybio Inc | formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| WO2014141149A1 (en) * | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulations with reduced viscosity |
| WO2014169153A1 (en) * | 2013-04-10 | 2014-10-16 | Echogen, Inc. | Peptide complexes and therapeutic uses |
| JP6179939B2 (ja) * | 2013-07-09 | 2017-08-16 | 国立大学法人 筑波大学 | 高濃度γグロブリン製剤の粘度低下方法 |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EP3200804A4 (en) | 2014-10-01 | 2018-04-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| EP3804747A1 (en) * | 2015-01-18 | 2021-04-14 | Gloriana Therapeutics, Inc. | Therapeutic protein formulations |
| PH12018500379B1 (en) | 2015-08-24 | 2022-11-23 | Glaxosmithkline Ip No 2 Ltd | Biopharmaceutical compositions |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| CA3063324A1 (en) | 2017-05-16 | 2018-11-22 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| CN113507938B (zh) | 2019-03-29 | 2024-04-16 | 广东恒瑞医药有限公司 | 包含抗il-5抗体的药物组合物及其用途 |
| JP2023533704A (ja) * | 2020-07-13 | 2023-08-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 高濃度タンパク質製剤用の粘度低減賦形剤及びそれらの組み合わせ |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5747447A (en) * | 1992-04-30 | 1998-05-05 | Cor Therapeutics | Stable polypeptide composition |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| EP1324776B2 (en) * | 2000-10-12 | 2018-03-21 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| AU2002319544B2 (en) | 2001-08-10 | 2008-07-10 | Aberdeen University | Antigen binding domains from fish |
| ATE352316T1 (de) * | 2002-11-01 | 2007-02-15 | Glaxosmithkline Biolog Sa | Immunogene zusammensetzung |
| US20050053666A1 (en) * | 2002-12-31 | 2005-03-10 | Stelios Tzannis | Antibody-containing particles and compositions |
| JP4869064B2 (ja) * | 2003-04-04 | 2012-02-01 | ジェネンテック， インコーポレイテッド | 高濃度抗体及びタンパク質製剤 |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| EP1962907A2 (en) * | 2005-12-21 | 2008-09-03 | Wyeth a Corporation of the State of Delaware | Protein formulations with reduced viscosity and uses thereof |
| US9084777B2 (en) * | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
| EP2129401B8 (en) * | 2006-12-21 | 2020-01-15 | Amgen Inc. | Stable buffered formulations containing polypeptides |
| ES2750254T3 (es) * | 2007-09-27 | 2020-03-25 | Amgen Inc | Formulaciones farmacéuticas |
| AR069495A1 (es) * | 2007-11-30 | 2010-01-27 | Glaxo Group Ltd | Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis) |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| PT3295957T (pt) * | 2010-01-15 | 2019-11-12 | Kirin Amgen Inc | Formulação de anticorpo anti il-17ra e regimes terapêuticos para o tratamento de psoríase |
| WO2011095543A1 (en) * | 2010-02-04 | 2011-08-11 | Csl Behring Ag | Immunoglobulin preparation |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| SG193964A1 (en) * | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
-
2012
- 2012-04-06 EP EP12768307.6A patent/EP2694100A4/en not_active Withdrawn
- 2012-04-06 AU AU2012240050A patent/AU2012240050B2/en not_active Ceased
- 2012-04-06 US US14/110,182 patent/US20140023655A1/en not_active Abandoned
- 2012-04-06 EP EP16154327.7A patent/EP3058952A1/en not_active Withdrawn
- 2012-04-06 SG SG2013072426A patent/SG193963A1/en unknown
- 2012-04-06 CN CN201280026486.5A patent/CN103596585A/zh active Pending
- 2012-04-06 WO PCT/US2012/032462 patent/WO2012138958A1/en not_active Ceased
- 2012-04-06 EA EA201391488A patent/EA201391488A1/ru unknown
- 2012-04-06 JP JP2014504013A patent/JP2014516924A/ja active Pending
- 2012-04-06 BR BR112013025866A patent/BR112013025866A2/pt not_active IP Right Cessation
- 2012-04-06 KR KR1020137029163A patent/KR20140018966A/ko not_active Withdrawn
- 2012-04-06 CA CA2832556A patent/CA2832556A1/en not_active Abandoned
-
2013
- 2013-09-29 IL IL228591A patent/IL228591A0/en unknown
-
2016
- 2016-04-14 AU AU2016202355A patent/AU2016202355A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516924A5 (cg-RX-API-DMAC7.html) | ||
| JP2014510152A5 (cg-RX-API-DMAC7.html) | ||
| KR102462041B1 (ko) | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 | |
| RU2020123963A (ru) | Стабилизированные препараты, содержащие антитела против ngf | |
| ES2885815T3 (es) | Nuevo formato biespecífico adecuado para su uso en el cribado de alto rendimiento | |
| JP2022087255A (ja) | キャリア結合剤組成物およびそれを作製および使用する方法 | |
| JP2019503349A5 (cg-RX-API-DMAC7.html) | ||
| CN114616249A (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| JP2024054251A (ja) | ヒト成長分化因子１５（ｇｄｆ－１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法 | |
| RU2011142184A (ru) | Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| JP2018521135A5 (cg-RX-API-DMAC7.html) | ||
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| RU2012131671A (ru) | Способ полипептидной модификации для очистки полипептидных мультимеров | |
| JP2014522843A5 (cg-RX-API-DMAC7.html) | ||
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| UA107211C2 (uk) | Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r) | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| ME02807B (me) | HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE | |
| RU2016129624A (ru) | Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера | |
| FI3310809T3 (fi) | Anti-cgrp-vasta-aineformulaatio | |
| JP2013543505A5 (cg-RX-API-DMAC7.html) | ||
| JP2020537520A5 (cg-RX-API-DMAC7.html) | ||
| RU2015123476A (ru) | Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения | |
| JP2016539096A5 (cg-RX-API-DMAC7.html) |